Aspirin May Lower PCa Mortality

Share this content:

Anticoagulant use may lower the risk of death from prostate cancer (PCa), according to a study of men who underwent radical prostatectomy (RP) or radiotherapy (RT).

After a median follow-up of 70 months, the likelihood of prostate cancer-specific mortality (PCSM) was significantly lower among 2,175 men receiving anticoagulants (warfarin, clopidogrel, enoxaparin and/or aspirin) than among 3,780 who were not receiving anticoagulants (3% vs. 8% at 10 years).

Both RP and RT patients experienced the benefit of anticoagulation therapy, Kevin S. Choe, MD, and colleagues reported online in the Journal of Clinical Oncology. In multivariate analysis, aspirin use was independently associated with 57% decreased risk of PCSM.

You must be a registered member of Renal and Urology News to post a comment.